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Tight regulation of NF-kB signaling is essential for
innate and adaptive immune responses, yet the
molecular mechanisms responsible for its negative
regulation are not completely understood. Here, we
report that NLRX1, a NOD-like receptor family mem-
ber, negatively regulates Toll-like receptor-mediated
NF-kB activation. NLRX1 interacts with TRAF6 or IkB
kinase (IKK) in an activation signal-dependent fash-
ion. Upon LPS stimulation, NLRX1 is rapidly ubiquiti-
nated, disassociates from TRAF6, and then binds to
the IKK complex, resulting in inhibition of IKKa and
IKKb phosphorylation and NF-kB activation. Knock-
down of NLRX1 in various cell types markedly
enhances IKK phosphorylation and the production
of NF-kB-responsive cytokines after LPS stimula-
tion. We further provide in vivo evidence that
NLRX1 knockdown in mice markedly enhances sus-
ceptibility to LPS-induced septic shock and plasma
IL-6 level. Our study identifies a previously unrecog-
nized role for NLRX1 in the negative regulation of
TLR-induced NF-kB activation by dynamically inter-
acting with TRAF6 and the IKK complex.
INTRODUCTION
The innate immune system serves as the first line of defense
against invading pathogens, such as bacteria and viruses, by
recognizing a limited but highly conserved set of molecular
structures, so-called pathogen-associated molecular patterns
(PAMPs) (Akira et al., 2006). Recognition of such PAMPs relies
on several classes of pattern recognition receptors (PRRs),
including Toll-like receptors (TLRs), NOD-like receptors (NLRs),
and RIG-I-like receptors (RLRs) (Akira et al., 2006; Meylan
et al., 2006; Rehwinkel and Reis e Sousa, 2010; Schroder and
Tschopp, 2010; Takeuchi and Akira, 2010; Ting et al., 2010).
Although different receptors recognize specific ligands, theligand-receptor binding generally leads to activation of common
downstream pathways such as NF-kB, MAPK, and type I inter-
feron to induce cytokine and chemokine gene expression, which
facilitate pathogen clearance. Tight regulation of these key
signaling pathways is essential for both innate and adaptive
immunity; otherwise, aberrant immune responses may occur,
leading to severe or even fatal bacterial sepsis, autoimmune,
and chronic inflammatory diseases (Karin et al., 2006; Liew
et al., 2005).
TLR activation usually results in the recruitment of adaptor
molecules, such as MyD88 and TRIF, which acts on a series
of downstream signaling molecules such as TRAF6, which
possesses E3 ubiquitin ligase activity. Activated TRAF6
synthesizes lysine 63 (K63)-linked polyubiquitin chains on itself
and other proteins, which then serves as a scaffold to recruit
TAK1 and the IkB kinase (IKK) complex through binding to the
TAB2 and NEMO, respectively (Skaug et al., 2009). In contrast,
activation of RIG-I and MDA-5 by double-stranded RNAs
or certain viruses results in recruitment of the MAVS protein
(mitochondrial antiviral signaling; also called VISA, IPS-1, and
Cardif) (Kawai et al., 2005; Meylan et al., 2005; Seth et al.,
2005; Xu et al., 2005). These signaling events converge on IKK
complex to trigger activation of NF-kB signaling pathway and
elicit inflammatory responses (Chen, 2005; Ha¨cker and Karin,
2006) (Akira et al., 2006) (Hayden and Ghosh, 2008). The IKK
complex consists of two catalytic subunits, IKKa and IKKb,
and one regulatory subunit, NEMO (also known as IKK-g).
Activation of the IKK complex involves phosphorylation of
serine residues on the activation loop of IKKa/b, and binding
of NEMO to polyubiquitin chains formed by upstream signals
(Skaug et al., 2009). However, the molecular mechanisms
involved in the negative regulation of IKK activation are not
well understood.
NLRX1, a member of the NLR family of proteins, contains an
N-terminal X domain, a nucleotide binding oligomerization do-
main (NOD) and a C-terminal leucine-rich repeat domain (LRR).
NLRX1 was shown to be a negative regulator of RIG-I-mediated
antiviral response, by binding to MAVS on mitochondria and
blocking its interaction with RIG-I (Moore et al., 2008). NLRX1
also modulates TNF-a and Shigella infection-induced reactive
oxygen species (ROS) release (Tattoli et al., 2008), but itsImmunity 34, 843–853, June 24, 2011 ª2011 Elsevier Inc. 843
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unknown. Here, we demonstrate that NLRX1 is a negative
regulator of TLR-mediated NF-kB signaling. In unstimulated
cells, NLRX1 interacts with TRAF6, but after LPS stimulation,
it undergoes K63-linked polyubiquitination and binds directly
to the IKK complex and inhibits the phosphorylation of IKK,
thus inhibiting NF-kB activation and proinflammatory cytokine
release. We further provide in vivo evidence showing that
specific knockdown of NLRX1 in mice enhances LPS-indsuced
proinflammatory cytokine induction and renders mice more
sensitive to LPS-induced septic shock. Thus, NLRX1 may serve
as a useful target for manipulating immune responses against
infectious or inflammation-associated diseases, including
cancer.
RESULTS
NLRX1 Negatively Regulates TLR-Induced NF-kB
Activation
To identify new molecules that might negatively regulate
the NF-kB signaling pathway, we used a NF-kB-luciferase
(NF-kB-luc) assay to screen a panel of candidates, including
NLR family members, for their abilities to regulate NF-kB activity.
TLR4, the NF-kB-luc reporter, an internal control Renilla
luciferase reporter (pRL-TK-luc), and the candidate genes were
cotransfected into HEK293T (293T) cells, which were then
treated with the TLR4 ligand LPS for 18 hr for activation of
NF-kB-luc activity. One of the proteins identified that inhibited
NF-kB activation was NLRX1, also known as NOD9 (Figure 1A).
We further confirmed NLRX1 inhibited NF-kB activation by
LPS at both early (6 hr) and late time points (24 hr) (Figure S1A
available online). Similar inhibitory effects were observed with
293T/TLR7 cells treated with CL-097 (a TLR7 ligand) when
NLRX1 was coexpressed (Figure 1A). NLRX1 was recently
shown to inhibit RIG-I-mediated type I interferon pathway by
interacting with MAVS and sequestering it from interaction with
RIG-I (Moore et al., 2008). Consistent with previous findings,
we showed that NLRX1 inhibited RIG-I or MAVS-induced
IFN-b-luc activity (Figure S1B). Because most TLRs use
MyD88 as the adaptor protein for downstream signal transduc-
tion (Takeuchi and Akira, 2010), we next tested whether NLRX1
could inhibit MyD88-mediated NF-kB activation, which is
independent of the MAVS-mediated pathway. As shown in
Figure 1B, MyD88 strongly activated NF-kB-luc activity in 293T
cells, but such activation was potently inhibited by NLRX1,
suggesting that it inhibits MyD88-mediated NF-kB activation.
To determine whether NLRX1 also inhibits NF-kB activation
induced by downstream signaling molecules engaged in TLR
signaling, we cotransfected 293T cells with TRAF6, TAK1/
TAB1, IKKa, IKKb, or NF-kB p65 subunit to activate the
NF-kB-luc reporter gene. We found that the activation of
NF-kB by TRAF6, TAK1, IKKa, and IKKb was markedly inhibited
by NLRX1, but not by the NLR family members NOD1 or NOD2
(Figure 1B). By contrast, NLRX1 did not inhibit p65-mediated
NF-kB activation, indicating that it may inhibit the NF-kB
pathway immediately upstream of p65, most likely by interfering
with the IKK complex.
To test the possibility that MAVS is required for NLRX1-
mediated inhibition of NF-kB signaling under physiological844 Immunity 34, 843–853, June 24, 2011 ª2011 Elsevier Inc.conditions, we determined IL-6 production in wild-type (WT)
and MAVS-deficient mouse embryonic fibroblasts (MEFs) after
LPS or poly(I:C) (a TLR3 ligand) treatment (Sun et al., 2006). As
shown in Figure 1C, IL-6 production was increased after LPS
or poly(I:C) treatment, but such increases were potently inhibited
by NLRX1 in both WT and MAVS-deficient MEFs, strongly
suggesting that NLRX1 inhibits IL-6 production through
a MAVS-independent pathway.
Because the mouse NLRX1 protein shares 75% amino acid
similarity with human NLRX1, we examined whether the inhibi-
tory function of NLRX1 is conserved between humans and
mice. Murine NLRX1 expression markedly inhibited NF-kB-luc
activation by different stimuli, suggesting a conserved biological
function by which NLRX1 regulates the NF-kB pathway (Fig-
ure S1C). To test whether the findings in 293T cells can be
extended to other cells, we performed NF-kB-luc reporter
assays in MEFs and THP-1 cells (human monocyte cell line),
which express endogenous TLR4. LPS treatment induced strong
NF-kB-luc activity in both cell lines, and such activity was
potently inhibited when NLRX1 was cotransfected (Figure 1D).
We further examined endogenous NF-kB DNA binding ability
by a gel mobility shift assay. IKKb expression activated endoge-
nous NF-kB to bind to DNA probe containing NF-kB binding
sites, but this activity was completely inhibited by NLRX1. By
contrast, p65-mediated NF-kB DNA-binding activity was not
affected by NLRX1, which is consistent with the luciferase
reporter assay (Figure 1E). Since NF-kB activation is also asso-
ciated with p65 translocation from the cytoplasm into the
nucleus of cells after LPS stimulation, we examined p65 translo-
cation in cells with or without NLRX1 expression. In cells trans-
fected with empty vector, p65 rapidly translocated from the
cytoplasm to the nucleus after LPS treatment. By contrast, p65
remained in the cytoplasm of the cells expressing NLRX1 after
LPS treatment (Figure 1F). Taken together, these results suggest
that NLRX1 inhibits TLR-induced NF-kB activation in various cell
types.
NLRX1 Dynamically Interacts with TRAF6 and the IKK
Complex in Response to LPS
To determine the molecular mechanisms by which NLRX1 nega-
tively regulates NF-kB signaling, we tested whether NLRX1
directly interacts with the TRAF family adaptor proteins because
different NF-kB activation signals use distinct TRAF proteins to
activate NF-kB signaling. Immunoprecipitation experiments
showed that NLRX1 interacted with TRAF6 and TRAF3, but not
with TRAF2 or TRAF5 (Figure 2A).
To furtherdetermine theendogenousprotein interactionsunder
physiological conditions, we developed an antibody against
NLRX1 and confirmed its specificity in 293T cells, RAW264.7
cells, and primary macrophages (Figure S2A–S2D). 293T/TLR4
cells transfectedwithFlag-taggedNLRX1 (F-NLRX1)were treated
with LPS and the cell lysates were harvested at different time
points. Anti-TRAF6 immunoprecipitation followed by anti-Flag
immunoblotting revealed that NLRX1 interacted with TRAF6 in
unstimulatedcells, but dissociated fromTRAF6after LPSstimula-
tion (Figure 2B). Similar results were obtained from RAW264.7
cells after LPS treatment (Figure 2C). To determine whether
NLRX1 interacts with endogenous TRAF3, we performed similar
experiments with anti-TRAF3, and found no endogenous
Figure 1. NLRX1 Inhibits TLR-Induced NF-kB Activation
(A) 293T cells were transfected with NF-kB-luciferase (luc) reporter plasmid and TLR4 or TLR7 plasmids, together with an pcDNA3.1 empty vector or NLRX1
construct, and analyzed for NF-kB-dependent luciferase activity (fold induction) after treatment with LPS (TLR4 ligand) or CL-097 (TLR7 ligand) for 18 hr.
(B) 293T cells were transfected with NF-kB-luc, MyD88, TRAF6, TAK1+TAB1, IKKa, IKKb, or p65, along with NLRX1, NOD1, or NOD2 and analyzed for
NF-kB-dependent luciferase activity at 36 hr posttransfection.
(C) WT andMAVS/MEFs were transfected with an empty vector or murine NLRX1 expression vector and then treated with LPS or poly (I:C). Cell supernatants
were used for measuring IL-6 release by ELISA.
(D) MEFs and human THP-1 cells were transfected with the NF-kB-luc reporter plasmid, along with an empty vector, murine NLRX1, or human NLRX1, and then
analyzed for NF-kB-dependent luciferase activity after LPS treatment.
(E) 293T cells were transfected with IKKb or p65 plasmids, together with an empty vector or NLRX1 plasmid. Nuclear extracts were used for detecting
endogenous NF-kB DNA binding activity by a gel-mobility shift assay. OCT-1-DNA complexes served as a loading control.
(F) RAW264.7 cells were transfected with an empty vector or murine NLRX1 plasmid. The localization of p65 was determined by immunostaining after 15 min of
LPS treatment. Data from (A)–(D) are plotted as means ± SD; *p < 0.05, **p < 0.01, ***p < 0.001, versus controls. All experiments were performed at least three
times.
Immunity
NLRX1 Inhibits NF-kB Signaling by Targeting IKK
Immunity 34, 843–853, June 24, 2011 ª2011 Elsevier Inc. 845
Figure 2. NLRX1 Dynamically Interacts with TRAF6 and
IKK Complex upon LPS Treatment
(A) 293T cells were transfectedwith F-TRAF2, F-TRAF3, F-TRAF5,
F-TRAF6, and HA-NLRX1. Flag-tagged proteins were immuno-
precipitated with anti-Flag followed by anti-HA immunoblotting.
IP, IB, and WCL denote immunoprecipitation, immunoblotting,
and whole-cell lysate, respectively.
(B and C), Cell extracts of 293T/TLR4 cells transfected with
Flag-NLRX1 (B) and RAW264.7 cells (C) were immunoprecipitated
with anti-TRAF6, respectively, then analyzed together with WCL
by IB with indicated antibodies.
(D) 293T cells were transfected with F-IKKa, F-IKKb, F-NEMO,
F-TRAF2, and HA-NLRX1. Flag-tagged proteins were immuno-
precipitated with anti-Flag and blotted with anti-HA.
(E–G) RAW264.7 cells (E), bone marrow-derived macrophages
(BMMs; F), or peritoneal macrophages (G) were treated with LPS
and the cell lysates were collected at the indicated time points and
used for immunoprecipitation with anti-NEMO or anti-NLRX1,
followed by immunoblotting with the indicated antibodies. Results
are representative of three independent experiments.
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poly(I:C) treatment, although the interaction between TRAF6
andNLRX1was readilydetectedbeforeLPSorpoly(I:C) treatment
(Figures S3A and S3B). These results suggest that NLRX1 inter-
acts with TRAF6, but not TRAF3, in unstimulated cells. After
activation,NLRX1mayswitch frombindingwithTRAF6 toanother
target protein in the NF-kB signaling pathway to inhibit its activa-
tion. Given that NLRX1 inhibits NF-kB activation induced by LPS,
MyD88, TRAF6, TAK1, and IKK, but not by p65, we reasoned that
it might directly interact with the IKK complex. To this possibility,
wecotransfected293TcellswithHA-taggedNLRX1 togetherwith
Flag-tagged IKKa, IKKb, and NEMO and tested their interaction.
Coimmunoprecipitation with anti-Flag and western blotting with
anti-HA revealed that NLRX1 interacted with IKKa, IKKb, and
NEMO, but not TRAF2 (Figure 2D).When IKKcomplexwas immu-
noprecipitated from RAW264.7 cell extracts with anti-NEMO, the
IKK-associated NLRX1 was barely detectable before LPS treat-
ment, but the interaction was increased and then peaked at
60 min after LPS treatment. Importantly, anti-NEMO immunopre-
cipitation also pulled down IKKa and IKKb (Figure 2E), suggesting
that NLRX1 interacts with the IKK complex only after LPS stimu-
lation.Similar resultswereobtainedwhenTHP1cellswere treated
withLPS (FigureS3C).WealsoobservedLPS-induced interaction
between IKK and NLRX1 in bone marrow-derived macrophages,
primaryMEFs, andprimarymouseperitonealmacrophageswhen
anti-NLRX1 was used for coimmunoprecipitation (Figures 2F
and 2G; Figure S3D). These results suggest that NLRX1 inhibits846 Immunity 34, 843–853, June 24, 2011 ª2011 Elsevier Inc.NF-kB signaling by its disassociation from TRAF6 and
interaction with TLR-activated IKK complex.
NLRX1 Is Ubiquitinated through a K63 Linkage
after LPS Treatment
Because NEMO binds to the K63-linked polyubiquitin
chains of TRAF6 after LPS treatment, we reasoned
that NLRX1 might undergo polyubiquitination, which
might affect the dynamic interaction among NLRX1,
TRAF6, and IKK. To test this possibility, we transfected
293T cells with plasmids expressing F-NLRX1 andHA-ubiquitin. Immunoprecipitation with anti-Flag and western
blotting with anti-HA revealed that NLRX1 was strongly ubiquiti-
nated (Figure 3A).Coexpression ofNLRX1withHA-ubiquitin (K48
only) or HA-ubiquitin (K63 only) mutant revealed that NLRX1 was
preferentially ubiquitinated through K63-linked polyubiquitin
chains (Figure 3A). Furthermore, we found that NLRX1 was
rapidly ubiquitinated through the K63 linkage by 10–15 min after
LPS treatment in 293/TLR4 andMEF cells, butwas then reduced.
By contrast, the K48-linked polyubiquitination of NLRX1 was not
affected by LPS treatment (Figures 3B and 3C), raising the possi-
bility that the polyubiquitin chains of NLRX1 is involved in the
recruitment of NEMO and its IKK complex.
To test this possibility, we first determine the domains respon-
sible for the interaction between NLRX1 and NEMO. We gener-
ated several deletion mutants of NLRX1 containing NOD and
LRR domains (NLRX1-NOD-LRR), LRR domain only (NLRX1-
LRR), the X and NOD domains (NLRX1-X-NOD), and the NOD
domain only (NLRX1-NOD) (Figure 3D). Immunoprecipitation
and western blot analyses revealed that NLRX1-FL, NLRX1-
NOD-LRR, NLRX1-LRR, and NLRX1-X-NOD, but not NLRX1-
NOD, could interact with NEMO (Figure 3E), suggesting that
the X and LRR domains are important for interaction with
NEMO. Interestingly, the mutants capable of interacting with
NEMO exhibited smear bands on the top of the gel, suggesting
that NEMO also binds to polyubiquitinated NLRX1.
NEMO contains an ubiquitin-binding domain (UBD), which
facilitates its binding to polyubiquitinatin chains of adaptor
Figure 3. NLRX1 Ubiquitination and Its Involvement in the Interac-
tion between NEMO and NLRX1
(A) 293T cells were transfected with HA-ubiquitin, HA-ubiquitin (K48 only),
HA-ubiquitin (K63 only), and F-NLRX1. Flag-NLRX1 was immunoprecipitated
with anti-Flag beads and blotted with anti-HA.
(B) 293T/TLR4 cells transfected with F-NLRX1 were collected at the indicated
timepoints after LPS treatment. Flag-NLRX1was immunoprecipitatedwithanti-
Flag beads and then analyzed by immunoblotting with indicated antibodies.
(C) MEF lysates were collected at the indicated time points after LPS treat-
ment. Endogenous NLRX1was immunoprecipitated with anti-NLRX1 and then
analyzed by immunoblotting with anti-K63-linked polyubiquitin antibody.
(D) Schematic diagram showing deletion constructs of NLRX1 containing
different domains.
(E) 293T cells were cotransfected with Flag-NEMO and the indicated
Myc-NRLX1 deletion constructs. Flag-taggedNEMOwas immunoprecipitated
with anti-Flag beads, and blotted with anti-Myc.
(F) 293T cells were cotransfected with HA-NLRX1 and the indicated Flag-
NEMO deletion constructs. Flag-tagged proteins were immunoprecipitated
with anti-Flag beads and blotted with anti-HA. Results are representative of
three independent experiments.
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et al., 2006). To test whether the UBD domain is required for
NEMO binding to NLRX1, we performed experiments with
NEMO deletion mutants. Coimmunoprecipitation experimentsshowed that smeared bands of NRLX1 protein were observed
in the immunoprecipitation with anti-NEMO in the cells trans-
fected with NEMO FL, NEMO 44-419, and NEMO 86-419, which
contain UBD domain. By contrast, NLRX1 pulled down with anti-
NEMO in the cells transfected with NEMO mutants without UBD
domain (i.e., NEMO 1-196 and NEMO 1-302) failed to show the
smear bands (Figure 3F). These results suggest that the K63-
linked polyubiquitination of NLRX1 is involved in the binding
of NEMO to NLRX1, thus facilitating the initial recruitment of
the NEMO/IKK complex to form a stable complex after LPS
stimulation.
LRR Domain of NLRX1 Binds to the Kinase Domain
of Activated, but Not Inactive, IKKb
Todetermine howNLRX1 interactswith IKKa and IKKb, we trans-
fected 293T cells with IKKa or IKKb with various NLRX1 deletion
mutants and then performed coimmunoprecipitation experi-
ments. Like NLRX1-FL, NLRX1-NOD-LRR, NLRX1-X-NOD, and
NLRX1-NOD interacted with IKKa and IKKb, whereas NLRX1-
LRR failed to interact with IKKa or IKKb (Figures 4A and 4B),
suggesting that the NOD domain of NLRX1 is required for the
binding of NLRX1 to IKKa and IKKb. However, functional assays
with NF-kB-luc reporter showed that NLRX1 constructs contain-
ing LRR domain (i.e., NLRX1-NOD-LRR and NLRX1-LRR) had
strong inhibitory activity, whereas NLRX1 mutants lacking LRR
domain (i.e., NLRX1-X-NOD and NLRX1-NOD) exhibited weak
or little inhibitory effect on NF-kB-luc activity (Figure 4C). These
results suggest that the NOD domain of NLRX1 is involved in its
interaction with IKK, but not for its inhibitory effect on IKKb-
induced NF-kB-luc activity. By contrast, the LRR domain of
NLRX1 could not bind to IKKa and IKKb, but is critically required
for its inhibitory effect on IKKb-induced NF-kB-luc activity. Thus,
a key question is how the NLRX1 LRR domain inhibits IKKb-
induced NF-kB-luc activity, given that it could not bind to IKKb.
One clue from the early results showing that NLRX1 binds to
IKK only after LPS stimulation (Figures 2E–2G) raises the possi-
bility that the NLRX1 LRR domain might bind to activated IKKa/
IKKb, rather than the inactive form of IKK. To test this possibility,
we transfected 293T cells with NLRX1 mutants and IKKb EE
mutant, a constitutive active form containing serine to glutamic
acid substitution on activation loop mimicking phosphorylation.
Indeed, we found that NLRX1-LRR could strongly bind to IKKb
EE (Figure 4D), suggesting that the NLRX1 LRR domain can
bind to the activated IKKb. To further determine the mechanisms
by which the NLRX1 LRR domain binds the activated IKKb (IKKb
EE), we reasoned that the activated IKKbmay undergoes confor-
mational changes and allow the LRR-interacting domain to be
exposed, as previously proposed (Hayden and Ghosh, 2008).
To test this possibility, we generated several IKKb deletion
mutants containing a kinase domain (KD), the leucine-zipper
domain (LZ), or helix-loop-helix domain (HLH). Coimmunopreci-
pitation and western blot analyses revealed that NLRX1 inter-
acted with the kinase domain of IKKb (IKKb-KD), but not with
IKKb-HLH or IKKb-LZ domain (Figure 4E). Importantly, we found
that the LRR domain, but not other domains, of NLRX1 exhibited
the strongest interaction with the kinase domain of IKKb
(IKKb-KD) (Figure 4F), suggesting that the LRR domain directly
binds to the kinase domain of IKKb when it becomes accessible
because of conformation changes after activation.Immunity 34, 843–853, June 24, 2011 ª2011 Elsevier Inc. 847
Figure 4. Mapping the Interaction Domains of NLRX1 and IKK
Subunits
(A and B) 293T cells were transfected with HA-IKKa (A) or HA-IKKb (B) and the
indicated F-NLRX1 deletion constructs. HA-tagged IKKa or HA-IKKb was
immunoprecipitated with anti-HA beads and blotted with anti-Flag.
(C) 293T cells were transfected withNF-kB-luc, IKKb, along with F-NLRX1 and
its deletion constructs and analyzed for NF-kB-dependent luciferase activity.
Data are plotted as means ± SD.
(D) Experiment performed as in (B), except that IKKbWTwas replaced by IKKb
EE mutant form.
(E) Identification of the kinase domain of IKKb interacting with NLRX1. The
upper panel shows a schematic diagram showing protein domain structures of
the IKKb deletions. KD, kinase domain; LZ, leucine zipper; HLH, helix-loop-
helix. As shown in the lower panel, 293T cells were cotransfected with
HA-NLRX1 with F-IKKb and its deletion constructs are indicated. Flag-tagged
Figure 5. NLRX1 Inhibits IKK Phosphorylation
(A) 293T cells transfected withHA-IKKa,HA-IKKb, and HA-p38 with or without
F-NLRX1 were used for analyzing the phosphorylation of IKKa/b and p38.
(B) 293T/TLR4 cells transfected with increasing amount of F-NLRX1 plasmid
were used to analyze the phosphorylation of IKKa/b after LPS treatment.
(C) RAW264.7 cells were treated with LPS, and cell lysates were collected at
the indicated time points for immunoprecipitation with anti-NLRX1 or anti-
NEMO, then immunoblotted with indicated antibodies or kinase assay (KA).
(D) 293T cells were transfected with HA-IKKb, together with an empty vector,
F-NLRX1, or its deletion constructs, and the phosphorylation of IKK was
determined. Results are representative of three independent experiments.
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and NF-kB Activation
To determine the mechanisms by which NLRX1 inhibits NF-kB
activation, we next cotransfected 293T cells with IKKa or IKKb
together with an empty vector or a NLRX1 expression vector.
As shown in Figure 5A, expression of IKKa or IKKb protein
strongly induced IKK autophosphorylation, as detected by the
phospho-specific IKK antibody. However, expression of
NLRX1 markedly inhibited the phosphorylation of IKKa and
IKKb. By contrast, the phosphorylation of p38 was not affected
by NLRX1 expression (Figure 5A), indicating that NLRX1 specif-
ically inhibits IKK phosphorylation, but not p38 phosphorylation.
Furthermore, NLRX1 inhibits LPS-induced IKK phosphorylation
in 293T/TLR4 cells in a dose-dependent manner (Figure 5B).
Because NLRX1 or its LRR domain preferentially binds to
activated form of IKKb and inhibits IKKb-induced NF-kB-luc
activity (Figures 4C–4F), we next sought to determine the
phosphorylation and kinase activity of IKKa/b in association
with either NEMO or NLRX1 in LPS-stimulated RAW264.7 cells.
We first immunoprecipitated NEMO-associated IKK complex
with anti-NEMO and NLRX1-associated IKK complex withproteins were immunoprecipitated with anti-Flag beads and then blotted with
anti-HA.
(F) Experiment performed as in (B), except IKKbWT formwas replaced by IKKb
KD mutant. Results are representative of three independent experiments.
Figure 6. Knockdown of NLRX1 Enhances IKK Phosphor-
ylation and NF-kB-Responsive Cytokine Gene Expression
(A) RAW264.7 cells were transfected with control siRNA or
NLRX1-specific siRNA, and then treatedwith LPS for the indicated
time points. LPS-induced IKK, IRF3, and MAPK (p38, JNK, and
ERK) activation were measured by IB with phosphospecific anti-
bodies and IKK activity was measured by KA.
(B) Quantitative comparison of signaling activation between
NLRX1 knockdown and control cells by density scanning of the
blots in (A).
(C) RAW264.7 cells were transfected with control siRNA or
NLRX1-specific siRNA, and then treated with LPS. The cytokine
Tnf-a and Il-6 gene expression in RAW264.7 cells induced by LPS
at different time points were determined by real-time PCR.
(D) Production of cytokine TNF-a and IL-6 in culture medium of
RAW264.7 cells transfected NLRX1-specific or control siRNAs
after LPS treatment. Data in (C and D) are plotted as means ± SD;
*p < 0.05, **p < 0.01, versus controls. All experiments were per-
formed at least three times with similar results.
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phorylation and kinase activities for IkBa phosphorylation. We
found that that NEMO-associated IKK complex displayed IKK
phosphorylation and kinase activity for IkBa phosphorylation,
as expected. By contrast, anti-NLRX1 immunoprecipitates
contain IKK (IKKa/IKKb and /NEMO) complex after LPS treat-
ment, but did not exhibit any IKK phosphorylation or kinase
activity for IkBa phosphorylation (Figure 5C). Consistent with
the results in Figure 4C, we found that the LRR domain-contain-
ing NLRX1 constructs (i.e., NLRX1-FL, NLRX1-NOD-LRR, and
NLRX1-LRR) strongly inhibited IKKb phosphorylation, whereas
NLRX1-X-NOD and NLRX1-NOD exhibited weak or no inhibitory
activity (Figure 5D). Taken together, these results suggest that
once NLRX1 (specifically its LRR domain) binds to the exposed
kinase domain of activated/phosphorylated IKK, NLRX1-associ-
ated IKK complexes lose the phosphorylation probably through
unknown phosphatases as well as their kinase activity for IkBa
phosphorylation under physiological conditions.
Knockdown of NLRX1 Enhances IKK Phosphorylation
and NF-kB-Responsive Genes
Because NLRX1 inhibits IKK phosphorylation and NF-kB acti-
vation, we reasoned that knockdown of NLRX1 would increase
IKK phosphorylation and NF-kB-responsive gene expression.
To test this prediction, we knocked down NLRX1 expression
by NLRX1-specific siRNA in RAW264.7 cells and stimulated
the cells with LPS (Figure S4A) and found that specific knock-
down of NRLX1 markedly enhanced IKK phosphorylation,
especially at 60 min after LPS stimulation, compared withImmuRAW264.7 cells transfected with control siRNA.
Kinase activity assays also showed increased and
prolonged IKK kinase activity for GST-IkBa phos-
phorylation in NLRX1 knockdown cells compared to
control siRNA-treated cells (Figure 6A). By contrast,
MAPK (p38, JNK, and ERK) signaling activation was
largely unchanged in the cells transfected with
NLRX1-specific or control siRNAs (Figure 6A). Simi-
larly, LPS treatment induced IRF3 activation, but
there was no difference in IRF3 phosphorylationbetween NLRX1 siRNA and control siRNA-treated cells (Fig-
ure 6A). To quantify these results, we did density scanning of
the protein bands, and found that only IKK phosphorylation
and kinase activity exhibited significant differences between
NLRX1 knockdown and control cells. There were no appre-
ciable differences in JNK, p38, EKR, and IRF3 phosphorylation
between NLRX1 knockdown and control cells (Figure 6B).
Conversely, LPS-induced IKK phosphorylation was markedly
inhibited when NLRX1 was overexpressed in RAW264.7 cells
(Figure S4B). Together, these results suggested that specific
knockdown of NLRX1 enhances LPS-induced IKK phosphory-
lation and NF-kB activation.
To determine whether increased NF-kB activation in the
NLRX1 knockdown cells could increase NF-kB-responsive
cytokine genes, we performed knockdown experiments in
RAW264.7 cells and found that Tnf-a and Il-6 gene expression
were significantly higher in NLRX1 knockdown cells than those
in control siRNA-transfected cells after LPS treatment (Fig-
ure 6C). Consistent with these results, the cytokine level of
TNF-a and IL-6 was increased in NLRX1 knockdown cells
compared to control cells (Figure 6D). Furthermore, NF-kB-
responsiveCcl2 andCxcl10 gene expressionwas also enhanced
in NLRX1 knockdown cells compared to control cells (Fig-
ure S4C). Similar results were observed with THP-1 cells trans-
fected with NLRX1-specific and control siRNAs (Figures S4D
and S4E). Taken together, these results suggest that specific
knockdown of NLRX1 increases IKK phosphorylation and
NF-kB-responsive cytokine gene expression in response to
LPS treatment.nity 34, 843–853, June 24, 2011 ª2011 Elsevier Inc. 849
Figure 7. NLRX1 Negatively Regulates NF-kB Signaling and Cytokine Response In Vivo
(A) Knockdown of murine NLRX1 expression in different tissues of NLRX1-KD mice as measured by quantitative real-time PCR.
(B) NLRX1 protein expression was determined by immunoblotting in WT and NLRX1-KD MEFs. WT and NLRX1-KD MEFs were infected by VSV-eGFP and then
visualized by fluorescent microscopy.
(C) WT and NLRX1-KD mice (n = 10 per group) were injected intravenously with poly(I:C) (200 mg per mouse) and then sera were collected at indicated times for
IFN-b measurement.
(D) LPS-induced IKK and MAPK activation in peritoneal macrophages from WT and NLRX1-KD mice. The quantified results are shown after band density
scanning.
(E) IL-6 production in WT and NLRX1-KD MEFs after treatment with LPS, Pam3CSK4 or infected with VSV-eGFP.
(F) IL-6 and TNF-a production in peritoneal macrophages from NLRX1-KD or WT mice after treatment with LPS.
(G) Survival of NLRX1-KD and WT mice (n = 9 per group) after peritoneal injection with LPS (30 mg/kg).
(H) Plasma IL-6 levels from WT and NLRX1-KD mice (n = 9 per group) at 3 hr after peritoneal injection with LPS (30 mg/kg). Data in (A, C, E, and F) are plotted as
means ± SD. *p < 0.05, **p < 0.01, versus controls. All experiments were performed at least three times with similar results.
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and Cytokine Response In Vivo
To substantiate the physiological function of NLRX1 in vivo, we
generated NLRX1 knockdown (NLRX1-KD) transgenic mice
constitutively expressing shRNA that specifically knocked
down mouse NLRX1 (Figure S5A). By comparison with the ubiq-
uitous expression ofNLRX1 in the tissues of wild-type (WT) mice,
mRNA transcript levels were markedly reduced in the thymus,
spleen, and bone marrow of NLRX1-KD mice (Figure 7A). More-850 Immunity 34, 843–853, June 24, 2011 ª2011 Elsevier Inc.over, in MEFs generated from NLRX1-KD mice, we found a
marked reduction of NLRX1 protein expression compared to
WT MEFs (Figure 7B). It has been reported that knockdown of
human NLRX1 in 293T cells enhances antiviral immunity and
inhibits virus replication (Moore et al., 2008). To determine
whether knockdown of mouse NLRX1 expression also contrib-
utes to antiviral immune responses, we infected MEFs with ves-
ticular stomatitis virus (VSV)-enhanced green fluorescence
protein (eGFP). VSV-eGFP infection was strongly inhibited in
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signal in the cells (Figure 7B). Similar results were obtained in
Nlrx1/ MEFs (Figure S5B). NLRX1-KD mice also produced
more interferon-b (IFN-b) in plasma, compared with WT mice
after intravenous injection of poly (I:C) (Figure 7C). To further
determine whether NLRX1 knockdown affects mouse survival
in response to viral infection, we injected NLRX1-KD and WT
mice with VSV-eGFP via the tail vein and then monitored their
survival. NLRX1-KD mice showed slightly but not significantly
increased mouse survival compared to WT mice (Figure S5C).
Consistent with this observation, we did not detect appreciable
differences in serum viral titers and cytokine (IFN-b and IL-6)
levels (Figures S5D–S5F). Together, these results suggest that
NLRX1 knockdown has some effects on type I interferon and
antiviral immunity in vitro, but not in vivo, thus raising the possi-
bility that NLRX1may have a predominant regulatory role in TLR-
induced NF-kB signaling.
To test this possibility, we isolated peritoneal macrophages
from WT and NLRX1-KD mice and examined IKK phosphoryla-
tion and MAPK signaling activation after LPS treatment. Con-
sistent with the results obtained with RAW264.7 cells, IKK
phosphorylation was much higher and prolonged in NLRX1-KD
macrophages compared to WT cells after LPS treatment,
whereas p38 and JNK phosphorylation was largely unchanged
(Figure 7D). To define the physiological function of NLRX1 in
response to other TLR ligands, we found that IL-6 production
was enhanced in NLRX1-KD MEFs after stimulation with LPS,
Pam3CSK4 (a TLR2 ligand), and infection with VSV-eGFP,
compared to WT MEFs (Figure 7E). Similarly, we found that
IL-6 expression was increased in Nlrx1/ MEFs compared to
WT MEFs treated with LPS, Pam3CSK4, poly (I:C), or CL-097
(Figures S6A and S6B). Furthermore, IL-6 and TNF-a production
in NLRX1-KD macrophages was significantly higher than those
in WT cells after treatment with LPS, Pam3CSK4, poly (I:C),
CL-097, and CpG (a TLR9 ligand) (Figure 7F; Figures S6C and
S6D). These results suggest that NLRX1-KD and Nlrx1/ cells
markedly enhance NF-kB signaling and cytokine (IL-6 and
TNF-a) production after TLR stimulation.
To determine the specificity of NLRX1 in inhibiting NF-kB acti-
vation, we compared NF-kB activation in NLRX1-KD and WT
cells induced by TNFR, T cell receptor (TCR), or B cell receptor
(BCR) stimulation. We did not observe an appreciable difference
in IL-6 production between NLRX1-KD and WT cells after TNF-a
treatment (Figure S6E). This result is consistent with immunopre-
cipitation experiments showing that NLRX1 interacted neither
with TRAF2 nor with IKK in cells treated with TNF-a (Figure 2A
and Figure S6F). Furthermore, we failed to find differences in
TCR- or BCR-induced NF-kB signaling between NLRX1-KD
and WT cells (Figures S6G and S6H), suggesting that NLRX1 is
not involved in TCR- or BCR-induced NF-kB activation.
We next sought to determine the function of NLRX1 in LPS-
induced septic shock. NLRX1-KD and WT mice were injected
with a high dose of Escherichia coli LPS (30mg/kg) intraperitone-
ally andmonitored for their survival. As shown in Figure 7G,more
than 80% of the NLRX1-KD transgenic mice died within 18 hr,
whereas all WT mice remained alive. All NLRX1-KD transgenic
mice died within 30 hr compared to50%of theWTmice, which
continued to survive after 36 hr (Figure 7G). Enhanced LPS
toxicity in NLRX1-KD mice correlated with markedly increasedplasma IL-6 level (Figure 7H). However, we did not observe
significant difference in plasma TNF-a level (data not shown).
These results provide in vivo evidence that NLRX1 negatively
regulates NF-kB activation, NF-kB-responsive cytokine IL-6,
and LPS-induced septic shock.
DISCUSSION
NLRX1 is a member of the NOD-like family of proteins, which are
characterized by a conserved NOD and LRR regions, and are
involved in the activation of diverse signaling pathways (Akira
et al., 2006; Inohara et al., 2005; Meylan et al., 2006; Ting and
Davis, 2005). Among these proteins, NOD1, NOD2, and NALP3
have been extensively studied and shown to activate inflamma-
some pathway once they encounter relevant PAMPs (Akira et al.,
2006; Inohara et al., 2005; Kobayashi et al., 2005; Meylan et al.,
2006; Shaw et al., 2008; Ting andDavis, 2005). However, the bio-
logical function of other NLR proteins remains poorly understood
(Ting et al., 2010). Previous report shows that NLRX1 functions
as a negative regulator of cellular antiviral immunity by interfering
with viral infection-induced RIG-I-MAVS complex formation or
modulates Shigella infection-induced reactive oxygen species
(ROS) generation (Moore et al., 2008; Tattoli et al., 2008). Our
studies, however, indicate that NLRX1 functions as a negative
regulator that inhibits TLR-induced NF-kB activation. The find-
ings presented here identify a previously unrecognized role for
NLRX1 in the negative regulation of NF-kB signaling by targeting
TRAF6 and IKK complex. Furthermore, we provide compelling
evidence that NLRX1 negatively regulates NF-kB signaling, cyto-
kine production, and LPS-induced septic shock in vivo.
In response to TLR stimulation, most TLRs recruit MyD88 and
activate the downstream molecules such as TRAF6, which acts
as an E3 ubiquitin ligase to catalyze K63-linked polyubiquitin
chain on itself. The polyubiquitin chains of TRAF6 function as a
scaffold to recruit the TAK1 and IKK complexes through binding
to the regulatory subunits TAB2 and NEMO, respectively (Skaug
et al., 2009). TLR-induced NF-kB signaling pathway has been
well characterized, but it is still not completely understood that
how the activated signals are dampened to prevent pathological
consequences, such as septic shock and inflammatory disor-
ders. The increased list of negative regulators of TLR signaling
(Komuro et al., 2008; Liew et al., 2005) includes diverse proteins
that regulate the TLR signaling pathway at different stages. The
deubiquitinating enzymes A20 and CYLD inhibit NF-kB signaling
by targeting TRAF6 upstream of IKK (Kovalenko et al., 2003;
Liew et al., 2005; Trompouki et al., 2003;Wertz et al., 2004), while
a recent report shows that CUEDC2 inhibits IKK activity by re-
cruiting a phosphatase PP1 and keeps IKK in an inactivated
status (Li et al., 2008). We recently reported that NLRC5 inhibits
TLR-induced NF-kB activation by constitutive interaction with
IKKa/b, but not NEMO (Cui et al., 2010). However, our results
here show that NLRX1 interacts with TRAF6 in unstimulated
cells, but disassociates from TRAF6 upon LPS stimulation. By
contrast, there was no interaction between NLRX1 and TRAF2
or TRAF3 before or after stimulation. In addition, NLRX1 did
not show any inhibitory effect on TNFR-, TCR-, or BCR-induced
NF-kB signaling, which is independent of TRAF6. These results
further suggest that NLRX1 specifically inhibits TLR-induced
TRAF6-dependent NF-kB signaling through targeting TRAF6.Immunity 34, 843–853, June 24, 2011 ª2011 Elsevier Inc. 851
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ciation from TRAF6 are not known, we found that NLRX1 is
rapidly ubiquitinated at 10–15min after LPS stimulation. Interest-
ingly, like TRAF6, NLRX1 also undergoes K63-linked, but not
K48-linked, polyubiquitination after LPS stimulation. The interac-
tion between NLRX1 and the IKK complex is induced after LPS
stimulation. Thus, the molecular mechanisms by which NLRX1
inhibits NF-kB signaling are distinct from NLRC5. It appears that
several negative regulators specifically target TRAF6 and/or
IKK to control NF-kB activation through distinct mechanisms.
Our results show that the K63-linked polyubiquitination of
NLRX1 may be involved in the dynamic interaction of NLRX1
with TRAF6 or with the IKK complex. NLRX1 polyubiquitination
may alter its interaction with TRAF6 and serve as a scaffold to
recruit the IKK complexes through binding to the regulatory
subunit NEMO. This notion is further supported by our results
showing that NEMO mutants lacking UBD domain fail to pull
down the polyubiquitinated NLRX1 (the smear bands). Further-
more, NLRX1 interacts only with constitutively active IKKb. IKK
activation has been proposed to depend on phosphorylation of
IKKb on its activation loop, which in turn might induce the com-
plex conformation change and exposure of kinase domain (Hay-
den and Ghosh, 2008). Indeed, we show that the LRR domain in
NLRX1 interacts strongly with the kinase domain of IKKb when
IKKb becomes accessible as a result of conformational changes
after IKK activation or phosphorylation. These results suggest
that the interactions of NLRX1 with TRAF6 or with the IKK
complex are complicated and are signaling dependent. On the
basis of these findings, we propose a working model: NLRX1
associates and disassociates with TRAF6, depending on the
activation status of cells. Upon stimulation with LPS, both
TRAF6 and NLRX1 are rapidly ubiquitinated through the K63
linkage and they dissociate from each other. The K63 linked
polyubiquitination of TRAF6 leads to the recruitment of the
TAK1 complex and IKK complex to polyubiquitin chains, acti-
vating IKK for its phosphorylation, which becomes the target of
NLRX1. The polyubiquitin chains of NLRX1 may serve as a scaf-
fold to recruit NEMO, and then NLRX1 binds to activated IKK and
forms a relatively stable NLRX1-IKK complex through the inter-
action between the NLRX1 LRR domain and the IKKb kinase
domain. Meanwhile, the phosphorylation of IKK is removed by
unknown phosphatases, resulting in formation of a NLRX1-IKK
complex without IKK phosphorylation and kinase activity.
Thus, the interactions of NLRX1 with TRAF6 or with the IKK com-
plex are a dynamic process and rely on TLR-induced activating
signal. To determine whether TRAF6 is responsible for NLRX1
ubiquitination, we performed experiments with WT and Traf6/
MEFs and found that NLRX1 is equally ubiquitinated in both
types of cells after LPS treatment (data not shown), suggesting
that TRAF6may not be the E3 ligase responsible for NLRX1 ubiq-
uitination. Thus, further studies are needed to identify such E3
ubiquitin ligases for the ubiquitinatination of NLRX1.
Although NLRX1 has been reported as amitochondria-associ-
ated protein, it is evident that some NLRX1 protein is present in
the cytoplasm to function as a negative regulator of NF-kB sig-
naling. Similar proteins such as Stat3 and Bcl-2 have been
reported to have different biological functions in the cytoplasm
and mitochondria (Gough et al., 2009; Hockenbery et al., 1993;
Jacobson et al., 1993;Wegrzyn et al., 2009). To define the biolog-852 Immunity 34, 843–853, June 24, 2011 ª2011 Elsevier Inc.ical function ofNLRX1 in vivo,wegeneratedNLRX1-KDmicewith
shRNA targeting NLRX1 expression. Our study using NLRX1-KD
mice, as well as cells derived from both NLRX1-KD and NLRX1
knockout mice, further provide evidence that NLRX1 is a critical
negative regulator of TLR-induced NF-kB signaling pathway.
Macrophages and MEFs from NLRX1-KD mice enhance IKK
phosphorylation and produce more proinflammatory cytokines
in response to TLR stimulation. More importantly, NLRX1-KD
mice aremore sensitive to LPS-induced septic shock, with asso-
ciation of increased level of plasma IL-6. Although we observed
enhanced antiviral immunity against VSV-eGFP infection in
NLRX1-KD and Nlrx1/ MEFs and increased IFN-b production
in NLRX1-KD mice after poly(I:C) injection, we did not observe
appreciable differences in mouse survival, viral titers, and serum
cytokine levels after VSV-eGFP infection. These results suggest
that NLRX1 may play a predominant role in TLR-induced NF-kB
signaling, compared with type I IFN pathway.
Collectively, the findings presented here identify a previously
unrecognized role for NRLX1 in the negative regulation of
NF-kB signaling and provide insights into molecular mecha-
nisms by which NLRX1 dynamically interacts with TRAF6 and
IKK in a signal-dependent fashion. Thus, NLRX1 may serve as
a therapeutic target for the treatment of infectious and autoim-
mune diseases, as well as cancer.
EXPERIMENTAL PROCEDURES
Transfection and Reporter Assay
293T cells, MEFs, and THP-1 cells were transfected with plasmids encoding
NF-kB luciferase or IFN-b luciferase, pRL-TK Renilla luciferase, and different
expression or control vectors. Lipofectamine 2000, lipofectamine LTX with
PLUS reagent (Invitrogen, Carlsbad, CA), and Amaxa nucleofector kit V (Lonza
Amaxa, Gaithersburg, MD) were used for tranfection of 293T cells, MEFs, and
THP-1 cells, respectively. The luciferase activity was determined by a dual
luciferase assay kit (Promega, Madison, WI) with a Luminoskan Ascent
luminometer (Thermo Scientific, Waltham, MA).
Immunoprecipitation and Immunoblot Analyses
For immunoprecipitation experiments, whole-cell extracts were prepared after
transfection or stimulation and incubated with indicated antibodies together
with Protein A/G beads (Pierce, Rockford, IL) for overnight. For anti-Flag
or anti-HA immunoprecipitation, anti-Flag or anti-HA agarose gels (Sigma,
St. Louis, MO) were used. Beads were thenwashed four timeswith lysis buffer,
and immunoprecipitates were eluted with SDS loading buffer (Cell Signaling
Technology, Danvers, MA) and resolved in SDS-PAGE gels. The proteins
were transferred to PVDF membrane (Bio-Rad) and further incubated with
the indicated antibodies. LumiGlo Chemiluminescent Substrate System from
KPL (Gaithersburg, MD) was used for protein detection.
Generation of NLRX1-KD Transgenic Mice
Plasmid DNA for NLRX1-specifc shRNA1 from Open biosystems (Huntsville,
AL) was linearized by restriction enzymes PvuI and XbaI digestion and injected
into fertilized mouse eggs of C57BL/6 strain through a Transgenic Core.
Positive founders and offspring were identified by genotyping PCR of the tail
DNA with the primers 50-ACGTCGAGGTGCCCGAAGGA-30 (forward) and
50-AAGCAGCGTATCCACATAGCGT-30 (reverse). Three transgenic lines were
maintained by crossing founders to C57BL/6. All the mice were maintained
in a pathogen-free animal facility. All animal studies performed were approved
by the BCM Institutional Animal Care and Use Committee.
Statistical Analysis
Unless indicated otherwise, all data were plotted as means ± SD. Significant
differences between groups were determined by two-tailed Student’s t test
or two-way ANOVA. In the mouse endotoxic shock study, Kaplan-Meier
Immunity
NLRX1 Inhibits NF-kB Signaling by Targeting IKKsurvival curves were generated and analyzed for statistical significance with
Graphpad Prism 4.0 software.
SUPPLEMENTAL INFORMATION
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and six figures and can be found with this article online at doi:10.1016/
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